Journal of Anaesthesiology Clinical Pharmacology

REVIEW ARTICLE
Year
: 2019  |  Volume : 35  |  Issue : 2  |  Page : 157--160

H3 antagonists and postoperative cognitive dysfunction


Chandrasekhar Krishnamurti 
 Department of Anesthesiology, NRI Institute of Medical Sciences, Visakhapatnam, Andhra Pradesh, India

Correspondence Address:
Chandrasekhar Krishnamurti
NRI Institute of Medical Sciences, Sangivalasa, Bheemli, Visakhapatnam - 531 162, Andhra Pradesh
India

Since histamine (HA) was first synthesized in 1907 and isolated as a bacterial contaminant of an extract of ergot in 1910, its role in health and disease and its molecular mechanism of action have been unraveled, leading to the formulation of an array of drugs with immense therapeutic value. HA is produced by decarboxylation of histidine, and its biological actions are mediated through four HA receptors, namely, H1, H2, H3, and H4 based on their sequence, their link to differential intracellular signaling mechanisms, and their unique pharmacological properties. H1 and H2 receptors have been targeted for treating allergic conditions and peptic ulcers, respectively. The discovery of a third HA receptor subtype (H3R) by molecular biologists in 1983, structurally a member of the G-protein-coupled receptor family, has led to the development of many potent and selective H3 receptor antagonists having the potential to treat a wide spectrum of neurological diseases including postoperative cognitive dysfunction.


How to cite this article:
Krishnamurti C. H3 antagonists and postoperative cognitive dysfunction.J Anaesthesiol Clin Pharmacol 2019;35:157-160


How to cite this URL:
Krishnamurti C. H3 antagonists and postoperative cognitive dysfunction. J Anaesthesiol Clin Pharmacol [serial online] 2019 [cited 2019 Jul 21 ];35:157-160
Available from: http://www.joacp.org/article.asp?issn=0970-9185;year=2019;volume=35;issue=2;spage=157;epage=160;aulast=Krishnamurti;type=0